A Phase Ib Trial of CB-839 in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Telaglenastat (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma
- Focus Adverse reactions
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 21 Feb 2019 Planned End Date changed from 31 Aug 2020 to 5 Dec 2022.
- 21 Feb 2019 Planned primary completion date changed from 31 Aug 2020 to 5 Dec 2022.